Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)



Status:Recruiting
Conditions:Breast Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:8/4/2018
Start Date:November 11, 2015
End Date:November 2020
Contact:Ayca Gucalp, MD
Phone:646-888-4536

Use our guide to learn which trials are right for you!

Phase I/II Trial of Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)

The purpose of this study is to test the safety and effectiveness of the investigational
drug, palbociclib with bicalutamide for the treatment of triple negative, androgen receptor
positive breast cancer.

The study therapy is to be self administered on an outpatient basis. Patients who meet
eligibility criteria and sign informed consent to Step 2 may begin treatment on study.
Treatment consists of bicalutamide orally once daily and palbociclib will be given orally
daily for 3 weeks on followed by 1 week off. A treatment cycle is considered to be 4 weeks.
Eligible patients will be evaluated for toxicity every 2 weeks during Cycle #1 and 2,
followed by every 4 weeks in subsequent cycles. Toxicity assessment will include history,
physical examination including vital signs, and laboratories including complete blood count
and comprehensive metabolic panel. Patients will keep a drug diary to document adherence to
oral therapy. Radiographic response evaluation per RECIST will occur every 8 weeks (2 cycles)
for cycles 1-6 and then every 12 weeks thereafter with high-resolution CT scan. Patients with
suspected bone-only lesions must have bone lesions assessed by CT with bone windows or by
bone scan at screening.

Phase I: We will use a standard 3+3 design for the dose finding lead in to establish the
recommended phase II doses for the combination of palbociclib and bicalutamide. The doses for
Phase I will be determined based on the dose level to which the patient is accrued.

Phase II: Treatment consists of bicalutamide orally once daily and palbociclib will be given
orally daily for 3 weeks on followed by 1 week off at the doses determined in phase I.

Inclusion Criteria:

A patient will be eligible for androgen receptor expression testing (STEP 1) if the
following criteria are met:

- Female

- Pathologically confirmed invasive cancer of the breast

- ER/PR status (ER or PR defined as positive if ≥1%; ER/PR is defined as negative if
<1%):

- Phase I: Patients may have ER/PR(-) breast cancer.

- HER2 normal (IHC 0-1; FISH < 2.0)

- Non-measurable or measurable, metastatic disease

- Available tissue for AR testing for research purposes

A patient will be eligible for participation in the therapeutic trial (STEP 2) if the
following criteria are met:

- Androgen receptor expression testing confirms that the patient's tumor is AR (+). AR
is considered positive if ≥1% of cell nuclei are immunoreactive using the Dako
antibody (clone AR441). Receptor testing may be performed on either primary tumor
specimen or tissue from a metastatic site. Local testing permitted for eligibility but
will require confirmation at MSKCC.

- There is no limit to the number of prior chemotherapy or endocrine therapy regimens
allowed. Patients with ER(+) AR(+) breast cancer must have had at least 1 prior line
of endocrine therapy to be eligible for the phase I portion of the trial.

- At least 2 weeks since last cytotoxic chemotherapy, hormonal therapy, or radiotherapy.
Toxicities related to prior therapy must either have returned to grade 1, or baseline
(excluding alopecia)

- Patient may receive bisphosphonates/denosumab for the palliation of bone metastases

- If patient has a history of brain metastases or leptomeningeal disease, lesions must
be stable for at least 3 months (as documented by either head CT or brain MRI)

- Prior treatment with bicalutamide will not be allowed

- At least 3 weeks from major surgery with full recovery

- ECOG performance status 0-2

- Age 18 years or greater

- Postmenopausal. Use of LHRH agonist permitted.

- Patients must not have another, non-breast, active malignancy that requires treatment.

- The effects of palbociclib on the developing human fetus at the recommended
therapeutic dose are unknown. Women of child-bearing potential must agree to use
adequate contraception (barrier method of birth control; abstinence). Women must not
breast feed while on study.

- Ability to understand and the willingness to sign a written informed consent document.

- Ability to swallow intact palbociclib capsules and bicalutamide tablets.

- Adequate organ and marrow function as defined below (ULN indicates institutional upper
limit of normal):

- Absolute neutrophil count ≥ 1.5 10^9/

- Hemoglobin ≥ 9.0 g/dL

- WBC ≥ 3.0 10^9/L

- Platelets ≥ 100 10^9/L

- Total bilirubin ≤ 1.5 ULN except for patients with known Gilbert syndrome

- AST(SGOT)/ALT(SGPT) ≤ 3 institutional ULN

- Plasma creatinine ≤ 1.5 ULN or Creatinine Clearance > 50 mL/min (calculated by
Cockcroft-Gault method)

- QTc interval ≤ 470 msec

Exclusion Criteria:

- Patients who have not recovered from adverse events of prior therapy to ≤ NCI
CTCAEv4.0 Grade 1.

- Patients receiving any other investigational anti-cancer agents.

- Patients who have received prior treatment with a selective CDK4/6 inhibitor

- Patients who have received prior anti-androgen therapy

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to palbociclib.

- Uncontrolled intercurrent illness including, but not limited to, known ongoing or
active infection, including HIV, active hepatitis B or C, symptomatic congestive heart
failure, unstable angina pectoris, cardiac arrhythmia (specifically, uncontrolled
atrial fibrillation or ventricular dysrhythmias except ventricular premature
contractions), or psychiatric illness/social situations that would limit compliance
with study requirements.

- Pregnant women and women who are breast-feeding.

- Patients with a history of long-QT syndrome or documented family history of long-QT
syndrome. Patients who must remain on drugs that prolong the QT interval.

- Palbociclib is a substrate of CYP3A. Caution should be exercised when dosing
palbociclib concurrently with CYP3A inducers or inhibitors. Furthermore, patients who
are taking concurrent medications that are strong inducers/inhibitors or substrates of
CYP3A4 should be switched to alternative medications to minimize any potential risk.
We found this trial at
5
sites
Basking Ridge, New Jersey
Phone: 646-888-4536
?
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Commack, New York 11725
Phone: 646-888-4536
?
mi
from
Commack, NY
Click here to add this to my saved trials
500 Westchester Avenue
Harrison, New York 10604
Phone: 646-888-4536
?
mi
from
Harrison, NY
Click here to add this to my saved trials
Middletown, New Jersey 07748
Phone: 646-888-4536
?
mi
from
Middletown, NJ
Click here to add this to my saved trials
1000 N Village Ave
Rockville Centre, New York 11570
(516) 256-3600
Phone: 646-888-4536
Memorial Sloan-Kettering at Mercy Medical Center Memorial Sloan Kettering Cancer Center Rockville Centre provides state-of-the-art...
?
mi
from
Rockville Centre, NY
Click here to add this to my saved trials